Название продукции:4-(1,3-dihydroxypropan-2-yl)-6-methoxypyrido[2,3-b]pyrazin-3-one
IUPAC Name:4-(1,3-dihydroxypropan-2-yl)-6-methoxy-3H,4H-pyrido[2,3-b]pyrazin-3-one
- CAS:1075237-97-6
- Молекулярная формула:C11H13N3O4
- Чистота:95%+
- Номер в каталоге:CM341757
- Молекулярная масса:251.24
Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:1075237-97-6
- Молекулярная формула:C11H13N3O4
- Точка плавления:-
- Smiles-код:O=C1C=NC2=CC=C(OC)N=C2N1C(CO)CO
- Плотность:
- Номер в каталоге:CM341757
- Молекулярная масса:251.24
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Pyridines
- Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
- Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
- Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
- Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
- Pyridopyrazines
- Among the heterocyclic compounds, pyridopyrazine compounds are widely used as intermediates in the preparation of advanced pharmaceutical materials with biological activity, and are the scaffolding materials that have been widely concerned by academia and industry in recent years. There are many pyridopyrazine derivatives on the market for the treatment of various pharmacological diseases.
Column Infos
- Gepotidacin
- GSK announces positive headline results from the EAGLE-1 Phase III trial for Gepotidacin in uncomplicated urogenital gonorrhea. Gonorrhoea is the second most common sexually transmitted infection due to the pathogen N. gonorrhoeae. Untreated urogenital gonorrhea can cause serious and permanent health problems, such as pelvic inflammatory disease and infertility.
Gepotidacin is an investigational, first-in-class inhibitor of bacterial topoisomerase. It has a distinct mechanism of action that inhibits bacterial DNA replication by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV. Gepotidacin confers activity against most strains of E. coli and S. saprophyticus, and N. gonorrhoeae, including target pathogens resistant to current antibiotics.